News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
Home
| News & Events |
|
Welcome to Debiopharm Group’s News & Events Center, aimed to give you immediate access to timely and relevant information about our company. In this section you will find information on our press releases, our Awards, a calendar of events, a list of our publications and a pdf of our corporate brochure.
|



